This announcement is a separate document:
科倫博泰生物-B:自願公告核心產品蘆康沙妥珠單抗(sac-TMT)於2024年美國臨床腫瘤學會年會上公佈的研究成果
SKB BIO-B: VOLUNTARY ANNOUNCEMENTSTUDY RESULTS FOR CORE PRODUCT SACITUZUMAB TIRUMOTECAN(SAC-TMT) AT 2024 ASCO ANNUAL MEETING
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.